share_log

Silence Therapeutics Says Its Thalassemia Therapy Candidate Demonstrated a Safe Profile in Phase 1 Trial

Silent Treateuticsは地中海貧血候補療法が1期試験で安全性を示すことを示した

MT Newswires ·  2022/09/29 07:28

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする